



Adding Smiles To Life

Date: November 27, 2025

To
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051, Maharashtra.
SYMBOL: QMSMEDI

Subject: Clarification on Observation regarding submission of Financial Results for the period ended 30-September-2025

Dear Sir/Madam,

This is with reference to your observation that the Company has not submitted the financial results for the quarter and half-year ended 30-September-2025 in a machine-readable format/legible copy.

We would like to clarify that the financial results were duly submitted within the prescribed timeline. However, due to a technical issue during the upload process, the document submitted may not have been in a machine-readable/fully legible format.

We have now taken corrective measures and re-submitted the financial results in the required machine-readable and clearly legible format to ensure full compliance with the applicable provisions.

We assure you that the Company remains committed to timely and accurate compliance with all listing regulations, and such an occurrence will be avoided going forward.

We request you to kindly take this on record.

For **QMS MEDICAL ALLIED SERVICES LIMITED**

Toral Jailesh Bhadra
(Membership Number: A56927)
(Company Secretary and Compliance Officer)
Place: Mumbai

QMS Medical Allied Services Ltd.

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 www.qmsmas.com

CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com

Independent Auditor's report on quarterly unaudited standalone financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of QMS Medical Allied Services Limited ("the Company") for the quarter and half year ended on September 30, 2025, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to issue a report on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Conclusion

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


Other Matter

6. The figures for the quarter ended September 30, 2025 are the balancing figures between the unaudited half year ended September 30, 2025 and unaudited figures for the quarter ended June 30, 2025 which were subject to limited review by us.

For H H Dedhia & Associates

Chartered Accountants

(FRN – 148213W)



Harsh H. Dedhia

Proprietor

M No. – 141494

UDIN – 25141494 BMLCPWG194



Place: Mumbai

Date: November 13, 2025

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India

Email: mm@qmsmas.com

Web: <https://qmsmas.com/>

Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30th September 2025. (Rs. In Lakhs)

Sl	Particulars	Quarter Ended			Six Months Ended			Year ended 31.03.2025
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	31.03.2025	30.09.2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Audited
1	Revenue From Operations							
(a)	Revenue From Operations (Net of taxes)	4,124.97	4,232.05	3,274.04	8,357.02	8,175.96	6,310.78	14,486.74
(b)	Other Income	0.26	15.20	9.35	15.46	25.37	20.21	45.58
	Total Income (net)	4,125.23	4,247.25	3,283.39	8,372.48	8,201.33	6,330.99	14,532.32
2	Expenses							
(a)	Cost of Material Consumed	-	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	2,645.33	2,731.30	1,843.76	5,376.63	4,350.41	3,755.77	8,106.18
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	-144.91	(189.38)	76.99	(334.29)	151.81	(113.18)	38.63
(d)	Employee Benefits Expenses	250.67	276.32	175.15	526.99	457.29	337.07	794.35
(e)	Finance Cost	173.11	176.06	106.86	349.16	404.52	191.01	595.53
(f)	Depreciation and Amortisation Expenses	82.84	75.79	82.77	158.63	180.31	159.51	339.83
(g)	Other Expenses	760.54	787.34	645.94	1,547.88	1,900.88	1,314.74	3,215.62
	Total Expenses	3,767.58	3,857.42	2,931.46	7,625.00	7,445.23	5,644.92	13,090.15
3	Profit before exceptional and extraordinary items and tax	357.65	389.83	351.93	747.48	756.10	686.07	1,442.17
4	Exceptional items	-	-	-	-	-	-	-
5	Profit before extraordinary items and tax	357.65	389.83	351.93	747.48	756.10	686.07	1,442.17
6	Extraordinary items	-	-	-	-	-	-	-
7	Profit before tax	357.65	389.83	351.93	747.48	756.10	686.07	1,442.17
8	Tax expense							
(a)	Current Tax	89.75	94.75	92.00	184.50	242.00	184.00	426.00
(b)	Deferred Tax	3.43	25.63	(1.25)	29.07	(28.33)	1.32	(27.01)
(c)	(Excess)/Short Provision for earlier years	-	-	-	-	1.06	0.05	1.12
	Total Tax Expense	93.18	120.38	90.75	213.57	214.73	185.37	400.10
9	Profit for the period from continuing operations	264.46	269.44	261.17	533.91	541.37	500.70	1,042.06
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-	-
11	Profit/(Loss) for the period	264.46	269.44	261.17	533.91	541.37	500.70	1,042.06
12	Details of Equity Share Capital							
	Paid up equity share capital (Face value of Rs.10/- each)	1,933.74	1,785.00	1,785.00	1,933.74	1,785.00	1,785.00	1,785.00
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	7,019.19
13	Earnings Per Equity Share (before extraordinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)							
(a)	Basic	1.45	1.48	1.44	2.93	2.98	2.76	5.73
(b)	Diluted	1.45	1.48	1.44	2.93	2.98	2.76	5.73
	See accompanying note to Financial Results							

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PANDURAJ MAKHIJA
Managing Director
DIN: 02700606



Date: 13.11.2025
Place: Mumbai



Adding Smiles To Life

Notes to Standalone Financial Statements

1. The above unaudited financial results of the company were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on 13.11.2025. The auditors have expressed an unmodified opinion on the said financial results.
2. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.
3. The standalone financial results for the quarter and half year ended on 30th September, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The Company is operating as a single segment company, engaged in "Healthcare Equipments/Supplies and Services" and hence there is no separate reportable business segment.
5. As per MCA notification dated 16 February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of capital & Disclosure Requirements) Regulations, 2009 are exempted from compulsory requirement of adoption of IND-AS, as the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. There are no Investor complaints pending as on 30th September 2025.
7. Statement includes the results for half year ended 30th September 2025 and corresponding figures for half year ended 31st March 2025. Also, the full year Audited results for the year ended 31st March, 2025 and corresponding figures for half year ended 30th September, 2024 is disclosed.
8. The figures for the quarter ended 30th September 2025 are balancing figures between the figures of the half year ended 30th September 2025 which were subject to limited review and figures for the quarter ended 30th June 2025.
9. The figures for the quarter ended 30th September 2024 are balancing figures between the figures of the half year ended 30th September 2024 which were subject to limited review and figures for the quarter ended 30th June 2024 which were subjected to limited review by statutory auditor.
10. Previous year figures have been regrouped/reclassified where required to make them comparable with figures of current period.
11. Earning Per share: Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualized.
12. Rights issue Note : The Board of Directors, at its meeting held on August 22, 2025, approved the proposal to raise funds up to ₹12.50 crores through a Rights Issue of equity shares. Subsequently, on August 25, 2025, the Board approved the said issue and filed the Draft Letter of Offer with the National Stock Exchange of India Limited (NSE).

Further, at the meeting held on August 29, 2025, the Board approved the detailed terms of the Rights Issue and the Letter of Offer, providing for the issue of 14,87,500 fully paid-up equity shares of face value ₹10 each at an issue price of ₹81 per share (comprising a premium of ₹71 per share).

Accordingly, on September 23, 2025, the Board considered and approved the allotment of 14,87,443 fully paid-up equity shares of face value ₹10 each at a price of ₹81 per share (including a premium of ₹71 per share), on a rights basis in the ratio of 1 (one) equity share for every 12 (twelve) fully paid-up equity shares held as on the record date, i.e., Thursday, September 4, 2025.

There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.

**For & on behalf of the Board of Directors of
QMS Medical Allied Services Limited**

Mahesh Makhija
Managing Director
[DIN: 02700606]



Place: Mumbai
Date: 13.11.2025

QMS Medical Allied Services Limited. (CIN L33309MH2017PLC299748)

**1A-1B / 2A-2B, Navkala Bharti Building, Plot No. 16, Prabhat Colony, Road No.3, Santacruz (East),
Mumbai - 400 055, ☎ +91-22-26288 1111,**

@ mm@qmsmas.com 🌐 www.qmsmas.com

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Standalone Assets and Liabilities

(Rs. In lakhs)

PARTICULARS		As at September 30,2025 (Unaudited)	As at March 31,2025 (Audited)
(I)	EQUITY AND LIABILITIES		
1)	Shareholders' Funds		
	(a) Share Capital	1,933.74	1,785.00
	(b) Reserves and Surplus	8,356.01	7,019.19
	(c) Money received against share warrants	-	-
2)	Non - Current Liabilities		
	(a) Long-term borrowings	2,488.56	2,759.87
	(b) Deferred tax liabilities (Net)	33.78	4.71
	(c) Other Long term liabilities	-	-
	(d) Long-term provisions	36.69	27.69
3)	Current Liabilities		
	(a) Short Term borrowings	5,773.03	5,084.57
	(b) Trade payables		
	Trade Payables-Micro and Small Enterprises	181.69	132.76
	Trade Payables- Other than Micro and Small Enterprises	1,093.82	1,524.64
	(c) Other Current liabilities	687.44	359.11
	(d) Short Term Provisions	228.50	205.48
		20,813.26	18,903.03
(II)	ASSETS		
1)	Non Current Assets		
	(a) Plant, Property and Equipment & Intangible Assets		
	(i) Plant, Property and Equipment	2,103.48	2,177.68
	(ii) Intangible assets	66.58	55.34
	(iii) Capital work-in-progress	-	-
	(iv) Intangible assets under development	292.79	292.79
	(b) Non Current Investments	4,528.01	4,528.01
	(c) Deferred tax assets (net)	-	-
	(d) Long Term Loans and Advances	1,450.00	295.00
	(e) Other Non Current Assets	158.34	101.72
2)	Current Assets		
	(a) Current investments	26.98	305.00
	(b) Inventories	4,169.54	3,927.71
	(c) Trade receivables	3,971.74	4,126.69
	(d) Cash and cash equivalents	118.57	38.69
	(e) Short-term loans and advances	340.92	344.49
	(f) Other Current Assets	3,586.33	2,709.93
		20,813.26	18,903.03

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PAHALRA MAKHIL
Managing Director
DIN: 02700606



Date: 13.11.2025

Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Standalone Cash Flow for the half year ended Septemeber 30, 2025

(Rs. In lakhs)

Sn	Particulars	For the Year ended	
		As at September 30,2025 (Unaudited)	As at September 30,2024 (Unaudited)
(A)	<u>OPERATING ACTIVITIES:</u>		
	Net Profit after tax	533.91	500.70
	(+) Current Tax	184.50	184.05
	(+/-) Deferred tax	29.07	1.32
	Net Profit before tax	747.48	686.07
	<u>Adjustments to reconcile profit before tax to net cash flows :</u>		
	Depreciation and amortisation expense	158.63	159.51
	Finance costs	161.93	33.05
	Interest on Loan and Fixed Deposit	(14.50)	(15.33)
	Profit on Sale of Fixed Assets	-	(1.64)
	Operating profit before working capital changes	306.05	175.60
	<u>Working capital adjustments</u>		
	Increase/(Decrease) in trade payables	(381.89)	(650.34)
	Increase/(Decrease) in Other current Liabilities	328.33	62.72
	Increase/(Decrease) in Provisions	32.02	109.47
	Increase/(Decrease) in Borrowings	688.17	786.09
	(Increase)/Decrease in Inventories	(241.83)	(113.18)
	(Increase)/Decrease in Trade receivables	154.95	904.50
	(Increase)/Decrease in Short Term loans and advances	3.57	(5.95)
	(Increase)/Decrease in Unpaid Dividend A/c	0.43	-
	(Increase)/Decrease in Other current Assets	(876.40)	(32.62)
	Cash generated from operations	(292.65)	1,060.70
	Income tax paid	(184.50)	(184.05)
	Net cash flow from operating activities	576.38	1,738.31
(B)	<u>INVESTING ACTIVITIES</u>		
	Purchase of property, plant and equipment and intangibles (including work in progress and capital advances)	(95.66)	(154.37)
	Investment in Fixed Deposits	(26.98)	(5.64)
	Investment in Shares of Subsidiary/ Advance paid for Investment in Shares of Subsidiary	(1,300.00)	(4,528.01)
	Deposits received back	(56.63)	22.91
	Loans advanced received back	145.00	30.00
	Redemption of Fixed Deposits	305.00	205.00
	Interest Income on Loan and Fixed Depsoit	14.50	15.33
	Sale of Fixed Assets	-	7.45
	NET CASH FLOWS FROM/ (USED) IN INVESTING ACTIVITIES	(1,014.77)	(4,407.32)
(C)	<u>FINANCING ACTIVITIES</u>		
	Loan repayment	(571.02)	(175.04)
	Finance cost paid	(161.93)	(33.05)
	Dividend Paid	(89.25)	-
	Acceptance of Loan	300.00	2,875.01
	Right Shares issued during the year	1,040.90	-
	NET CASH FLOWS FROM/ (USED IN) FINANCING ACTIVITIES	518.70	2,666.91
	NET INCREASE / (DECFASE) IN CASH & CASH EQUIVALENTS (A+B+C)	80.31	(2.10)
	Cash & Cash Equivalents at the beginning of the year	37.97	25.54
	Cash & Cash Equivalents at the end of the Period	118.28	23.44

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH P. HALRAJ MAKHIA
Managing Director
DIN: 02700606



Date: 13.11.2025
Place: Mumbai

Limited Review Report on quarterly unaudited consolidated financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of QMS Medical Allied Services Limited (hereinafter referred to as "the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended on September 30, 2025, attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Parent's Management and approved by the Board of Directors of the Parent, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to express a conclusion on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. Statement includes the results of the following entities:



Sr. No.	Name of Entity	Relationship
1	Saarthi Healthcare Private Limited	Subsidiary

Conclusion

5. Based on our review conducted and procedures performed as stated in paragraph 4 above and based on the management certified financial statements referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

6. We did not review the interim financial information/ financial results of subsidiary included in the statement, whose interim financial information/ financial results reflects total income of Rs. 992.54 lakhs, total net profit after tax of Rs. 138.93 lakhs for the half year ended September 30, 2025, as considered in the statement. These interim financial information/ financial results have been certified by management which have been furnished to us by the Parent's management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of the other auditor and procedures performed by us stated in paragraph 4 above. Our conclusion is not modified in respect of this matter.
7. The figures for the quarter ended September 30, 2025 are the balancing figures between the unaudited half year ended September 30, 2025 and unaudited figures for the quarter ended June 30, 2025 which were subject to limited review by us.

For H H Dedhia & Associates
Chartered Accountants
(FRN – 148213W)



Harsh H. Dedhia
Proprietor

M No. – 141494

UDIN – 25141494 BmLCfX2000



Place: Mumbai

Date: November 13, 2025

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India

Email: nm@qmsmas.com

Web: <https://qmsmas.com/>

Statement of Unaudited Consolidated Financial Results for the quarter and half year ended 30th September 2025, (Rs. In Lakhs)

Sl	Particulars	Quarter Ended			Six Months Ended			Year ended 31.03.2025
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	31.03.2025	30.09.2024	
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	
1	Revenue From Operations							
(a)	Revenue From Operations (Net of taxes)	4,470.00	4,649.50	3,719.88	9,119.50	8,844.78	6,756.63	15,601.41
(b)	Other Income	21.84	31.94	32.78	53.79	127.94	43.64	171.58
	Total Income (net)	4,491.84	4,681.45	3,752.66	9,173.29	8,972.73	6,800.27	15,772.99
2	Expenses							
(a)	Cost of Material Consumed	-	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	2,696.73	2,782.51	1,844.36	5,479.24	4,369.92	3,756.37	8,126.29
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	(139.93)	(189.38)	76.99	(329.31)	146.84	(113.18)	33.66
(d)	Employee Benefits Expenses	301.70	332.93	258.00	634.63	538.40	419.92	958.31
(e)	Finance Cost	135.55	142.40	106.93	277.95	272.50	191.08	463.58
(f)	Depreciation and Amortisation Expenses	93.87	85.80	83.62	179.67	222.18	160.37	382.54
(g)	Other Expenses	919.59	1,079.16	816.45	1,998.75	2,457.14	1,485.25	3,942.39
	Total Expenses	4,007.51	4,233.41	3,186.35	8,240.92	8,006.97	5,899.81	13,906.78
3	Profit before exceptional and extraordinary items and tax	484.33	448.04	566.32	932.37	965.75	900.46	1,866.21
4	Exceptional items	-	-	-	-	-	-	-
5	Profit before extraordinary items and tax	484.33	448.04	566.32	932.37	965.75	900.46	1,866.21
6	Extraordinary items	-	-	-	-	-	-	-
7	Profit before tax	484.33	448.04	566.32	932.37	965.75	900.46	1,866.21
8	Tax expense							
(a)	Current Tax	123.57	107.20	144.62	230.77	323.07	236.62	559.69
(b)	Deferred Tax	3.26	25.51	(1.63)	28.76	(49.60)	0.94	(48.66)
(c)	(Excess)/Short Provision for earlier years	-	-	-	-	(14.71)	0.05	(14.66)
	Total Tax Expense	126.83	132.71	142.98	259.54	258.77	237.60	496.37
9	Profit for the period from continuing operations	357.51	315.33	423.33	672.84	706.98	662.86	1,369.84
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-	-
11	Profit/(Loss) for the period	357.51	315.33	423.33	672.84	706.98	662.86	1,369.84
	Profit for the period attributable to:							
	Owners of the company	311.92	292.85	343.87	604.76	625.83	583.40	1,209.23
	Non-controlling Interest	45.59	22.49	79.46	68.07	81.15	79.46	160.61
12	Details of Equity Share Capital							
	Paid up equity share capital (Face value of Rs.10/- each)	1,933.74	1,785.00	1,785.00	1,933.74	1,785.00	1,785.00	1,785.00
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-	7,186.36
13	Earnings Per Equity Share (before extraordinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)							
(a)	Basic	1.71	1.61	1.89	3.32	3.44	3.21	6.65
(b)	Diluted	1.71	1.61	1.89	3.32	3.44	3.21	6.65
	See accompanying note to Financial Results							

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PAHAURAJ MAHILJA
Managing Director
DIN: 02700606

Date: 13.11.2025
Place: Mumbai





Adding Smiles To Life

Notes:

1. The above unaudited consolidated financial results of the company were reviewed and recommended by the audit committee on 13.11.2025 and subsequently approved by the Board of Directors at its meeting held on 13.11.2025. The review report has been filed with stock exchange and is available on the Company's website.
2. The figures for the quarter and half year ended 30th September, 2025 are balancing figures between the unaudited figures of the half year and the published year to date figures of the first quarter of the financial year which are subjected to limited review.
3. The consolidated financial results for the quarter ended 30th September, 2025 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued an unmodified report on unaudited financial results.
4. The above consolidated financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ('SEBI'), and the Accounting Standards (AS) prescribed under Section 133 of the Companies Act, 2013.
5. The Parent Company's and its subsidiary company's only identifiable reportable segment is "Healthcare Equipments/Supplies & Services" and hence disclosure of Segment wise information is not applicable under Accounting Standard – 17 "Segment Reporting".
6. Previous periods / year figures are regrouped and rearranged wherever necessary including on account of amendment in Division II to Schedule III of Companies Act 2013 to conform current period presentation.
7. Earning Per share: Earning Per share is calculated on the weighted average of the share capital received by the company. Half yearly EPS is not annualized.
8. Rights issue Note: The Board of Directors, at its meeting held on August 22, 2025, approved the proposal to raise funds up to ₹12.50 crores through a Rights Issue of equity shares. Subsequently, on August 25, 2025, the Board approved the said issue and filed the Draft Letter of Offer with the National Stock Exchange of India Limited (NSE).

Further, at the meeting held on August 29, 2025, the Board approved the detailed terms of the Rights Issue and the Letter of Offer, providing for the issue of 14,87,500 fully paid-up equity shares of face value ₹10 each at an issue price of ₹81 per share (comprising a premium of ₹71 per share).

Accordingly, on September 23, 2025, the Board considered and approved the allotment of 14,87,443 fully paid-up equity shares of face value ₹10 each at a price of ₹81 per share (including a premium of ₹71 per share), on a rights basis in the ratio of 1 (one) equity share for every 12 (twelve) fully paid-up equity shares held as on the record date, i.e., Thursday, September 4, 2025.

There has been no deviation in the use of proceeds of the Rights Issue, from the objects stated in the Offer document.

9. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.

**For & On behalf of the Board of Directors
of QMS Medical Allied Services Limited.**

Mahesh Makhija
Managing Director
[DIN: 02700606]



Place: Mumbai
Date: 13.11.2025

QMS Medical Allied Services Limited. (CIN L33309MH2017PLC299748)

1A-1B / 2A-2B, Navkala Bharti Building, Plot No. 16, Prabhat Colony, Road No.3, Santacruz (East),
Mumbai – 400 055, ☎ +91-22-26288 1111,

@ mm@qmsmas.com 🌐 www.qmsmas.com

QMS MEDICAL ALLIED SERVICES LIMITED

CIN: L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz
East Mumbai 400055, Maharashtra, India

Email: mm@qmsmas.com

Statement of Consolidated Assets and Liabilities

(Rs. In lakhs)

Sr.	Particulars	As at 30.09.2025	As at 31.03.2025
		Unaudited	Audited
I	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
(a)	Share Capital	1,933.74	1,785.00
(b)	Reserves and Surplus	8,594.02	7,186.36
(c)	Money received against share warrants		
	Minority Interest	1,806.98	1,738.91
	Sub-total - Shareholders' funds	12,334.75	10,710.26
2	Share application money pending allotment		
	Sub-total - Share application money pending allotment	-	-
3	Non-Current Liabilities		
(a)	Long-Term Borrowings	720.65	943.98
(b)	Deferred Tax Liabilities (Net)	12.84	(15.93)
(c)	Other Long Term Liabilities	-	-
(d)	Long Term Provisions	36.69	27.69
	Sub-total - Non-current liabilities	770.18	955.75
4	Current Liabilities		
(a)	Short-Term Borrowings	5,773.03	5,084.57
(b)	Trade Payables	-	-
	i. Total outstanding dues of micro enterprises and small enterprises	184.51	136.09
	ii. Total outstanding dues of creditors other than micro enterprises and small enterprises	1,163.59	1,553.44
(c)	Other Current Liabilities	587.07	348.80
(d)	Short Term Provisions	184.20	190.58
	Sub-total - Current liabilities	7,892.39	7,313.48
	TOTAL - EQUITY AND LIABILITIES	20,997.32	18,979.49
B	ASSETS		
1	Non Current Assets		
(a)	Property, Plant & Equipment and Intangible Assets		
	i. Property, Plant & Equipment	2,228.78	2,301.14
	ii. Intangible Assets	88.00	81.32
	iii. Capital Work-in-Progress	-	-
	iv. Intangible Assets under development	292.79	292.79
	v. Goodwill on acquisition	2,885.28	2,885.28
(b)	Non-Current Investments	-	-
(c)	Deferred tax assets (net)	-	-
(d)	Long-Term Loans and Advances	2,479.15	1,289.78
(e)	Other non-current assets	182.61	125.88
	Sub-total - Non-current assets	8,156.61	6,976.18
2)	Current Assets		
(a)	Current Investments	117.21	323.23
(b)	Inventories	4,169.54	3,932.68
(c)	Trade Receivables	4,157.97	4,324.13
(d)	Cash & Cash Equivalents	213.80	106.52
(e)	Short-Term Loans and Advances	340.92	344.49
(f)	Other Current Assets	3,841.28	2,972.26
	Sub-total - Current assets	12,840.71	12,003.31
	TOTAL - ASSETS	20,997.32	18,979.49

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606



Date: 13.11.2025

Place: Mumbai

QMS MEDICAL ALLIED SERVICES LIMITED

Regd. Office: Office No A1 A2/B1 B2, Navkala Bharti Bldg, Plot No16, Prabhat Colony, Opp near Santacruz Bus depot, Santacruz East, Mumbai - 400055.

CIN No: L33309MH2017PLC299748

Statement of Consolidated Cash Flow for the half year ended Septemeber 30, 2025

(Rs. In lakhs)

Sn	Particulars	For the Year ended	
		As at September 30,2025 (Unaudited)	As at September 30,2024 (Unaudited)
(A)	<u>OPERATING ACTIVITIES:</u>		
	Net Profit after tax	672.84	662.86
	(+) Current Tax	230.77	236.67
	(+/-) Deferred tax	28.76	0.94
	Net Profit before tax	932.37	900.46
	<u>Adjustments to reconcile profit before tax to net cash flows :</u>		
	Depreciation and amortisation expense	179.67	160.37
	Finance costs	90.65	33.05
	Interest on Loan and Fixed Deposit	(52.83)	(38.76)
	Profit on Sale of Fixed Assets	-	(1.64)
	Operating profit before working capital changes	217.48	153.02
	Working capital adjustments		
	Increase/(Decrease) in trade payables	(341.44)	(788.96)
	Increase/(Decrease) in Other current Liabilities	238.27	178.06
	Increase/(Decrease) in Provisions	2.62	114.27
	Increase/(Decrease) in Borrowings	688.17	786.09
	(Increase)/Decrease in Inventories	(236.86)	(113.18)
	(Increase)/Decrease in Trade receivables	166.16	810.01
	(Increase)/Decrease in Short Term loans and advances	3.57	(5.95)
	(Increase)/Decrease in Other current Assets	(869.02)	(102.41)
	(Increase)/Decrease in Unpaid Dividend A/c	0.43	-
	Cash generated from operations	(348.09)	877.93
	Income tax paid	(230.77)	(236.67)
	Net cash flow from operating activities	571.00	1,694.75
(B)	<u>INVESTING ACTIVITIES</u>		
	Purchase of property, plant and equipment and intangibles (including work in progress and capital advances)	(113.99)	(165.46)
	Loans/Deposits advanced during the year	(34.37)	-
	Investment in Fixed Deposits	(98.98)	(5.64)
	Investment in Shares of Subsidiary/ Advance for purchase of shares in subsidiary	(1,300.00)	(4,528.01)
	Deposits received back	(56.73)	45.86
	Loans advanced received back	145.00	30.00
	Redemption of Fixed Deposits	305.00	286.77
	Interest Income on Loan and Fixed Depsoit	52.83	38.76
	Sale of Fixed Assets	-	7.45
	NET CASH FLOWS FROM/ (USED) IN INVESTING ACTIVITIES	(1,101.24)	(4,290.27)
(C)	<u>FINANCING ACTIVITIES</u>		
	Loan repayment	(523.04)	(175.04)
	Finance cost paid	(90.65)	(33.05)
	Dividend Paid	(89.25)	-
	Acceptance of Loan	300.00	2,803.44
	Right Shares issued during the year	1,040.90	-
	NET CASH FLOWS FROM/ (USED IN) FINANCING ACTIVITIES	637.96	2,595.35
	NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	107.72	(0.17)
	Cash & Cash Equivalents at the beginning of the year	105.80	48.37
	Cash & Cash Equivalents at the end of the Period	213.52	48.20

FOR QMS MEDICAL ALLIED SERVICES LIMITED


Mr. MAHESH RAHAMRAO MAKHLJA
Managing Director
DIN: 02700606



Date: 13.11.2025
Place: Mumbai